Category: Company News
-

CANEX Metals Secures Court Ruling Invalidating Helix Joint Venture at Gold Basin Property
CANEX Metals (USOTC:NOMNF) has secured a British Columbia Supreme Court ruling declaring the Helix Resources joint venture agreement unenforceable, removing a legal dispute over rights to its Gold Basin gold project in Arizona as the company advances exploration and drilling preparations. Key Investor Takeaways Why NOMNF Stock Is in Focus CANEX Metals has confirmed that…
-

Rona Therapeutics Signs Global RNAi Licensing Agreement with Roche Worth Up to $1.16 Billion in Milestones
Roche (USOTC:RHHBY) has secured exclusive worldwide rights to Rona Therapeutics’ investigational ALK7-targeting RNA interference therapy for obesity and metabolic diseases, expanding its pipeline with a treatment approach focused on fat tissue rather than appetite regulation. Key Investor Takeaways Why RHHBY Stock Is in Focus Rona Therapeutics has granted Roche an exclusive worldwide licence to develop…
-

Rail Vision to Present AI Rail Safety Technology and Commercial Progress at LD Micro Conference
Rail Vision (NASDAQ:RVSN) will present its latest AI-powered railway safety solutions and commercial developments at the 20th Annual LD Micro Main Event on October 21, 2026, providing investors with an opportunity to assess its expanding product portfolio and North American market activities. Key Investor Takeaways Why RVSN Stock Is in Focus Rail Vision has confirmed…
-

Scinai Expands CDMO Business with $5.1 Million Manufacturing Agreement as Committed Orders Rise 300%
Scinai Immunotherapeutics (NASDAQ:SCNI) has secured a $5.1 million development and clinical manufacturing agreement with a US-listed biotechnology company, increasing its committed customer orders to approximately $7.6 million and improving revenue visibility through 2027. Key Investor Takeaways Why SCNI Stock Is in Focus Scinai Immunotherapeutics has expanded its contract development and manufacturing organisation (CDMO) business through…
-

Bumble Agrees to $1.3 Billion All-Cash Acquisition by Ithaca Holdings at $6.05 Per Share
Bumble Inc. (NASDAQ:BMBL) has agreed to be acquired by Ithaca Holdings in a $1.3 billion transaction, offering shareholders a substantial premium and setting the dating platform on a path toward private ownership. Key Investor Takeaways Why BMBL Stock Is in Focus Bumble has entered into a definitive agreement to be acquired by Ithaca Holdings, marking…
-

Pinnacle Food Group Completes First Bench-Scale Fermentation of Recombinant Human Lactoferrin
Pinnacle Food Group (NASDAQ:PFAI) has confirmed recombinant human lactoferrin production using methanol-free fermentation technology, marking an early technical milestone in its precision fermentation programme and supporting further development toward potential commercial scale-up. Key Investor Takeaways Why PFAI Stock Is in Focus Pinnacle Food Group has completed its first controlled bench-scale fermentation of recombinant human lactoferrin…
-

BIO-key Appoints Stephen Morrow President of PortalGuard to Advance IAM Platform Growth
BIO-key International (NASDAQ:BKYI) has appointed cybersecurity executive Stephen Morrow to lead its flagship PortalGuard identity and access management platform, with a focus on expanding enterprise adoption and channel partnerships. Key Investor Takeaways Why BKYI Stock Is in Focus BIO-key International has appointed Stephen Morrow as President of PortalGuard, its principal IAM software platform, as the…
-

Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion
Dianthus Therapeutics (NASDAQ:DNTH) has earned its first place on Fortune’s Best Workplaces in BioPharma list, highlighting its employee culture as the clinical-stage biotechnology company continues expanding its workforce. Key Investor Takeaways Why DNTH Stock Is in Focus Dianthus Therapeutics has been included in Fortune’s 2026 Best Workplaces in BioPharma ranking for the first time, recognising…
-

Biodexa Reaches 100-Patient Enrollment Milestone in Phase 3 Serenta Trial as Key Analysis Timeline Accelerates
Biodexa Pharmaceuticals (NASDAQ:BDRX) has enrolled 100 patients in its registrational Phase 3 Serenta trial of eRapa for Familial Adenomatous Polyposis, with an interim futility analysis and database lock now potentially occurring earlier than originally anticipated. Key Investor Takeaways Why BDRX Stock Is in Focus Biodexa has reached a new recruitment milestone in its Phase 3…
-

Kraig Biocraft Laboratories Seeks Production Expansion as Spider Silk Output Reaches New Records
Kraig Biocraft Laboratories has applied to expand its production subsidiary’s investment licence after reporting record spider silk output, as the company works to convert manufacturing progress into sustained commercial supply. Key Investor Takeaways Why KBLB Stock Is in Focus Kraig Biocraft Laboratories (USOTC:KBLB) is advancing its spider silk production expansion through an application for an…